# A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

> **NCT01482390** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 80 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Mericitabine
- **DRUG:** Peginterferon Alfa-2a
- **DRUG:** Placebo
- **DRUG:** Telaprevir

## Key facts

- **NCT ID:** NCT01482390
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2014-01-31
- **Final completion:** 2014-01-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482390, "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01482390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*